VDRL, Spinal Fluid
Use
The test is useful for diagnosing neurosyphilis by detecting reaginic antibodies in cerebrospinal fluid (CSF) using a nontreponemal serologic test. This is associated with conditions such as pleocytosis and elevated protein in patients with prior syphilis infection. A positive VDRL result on spinal fluid is highly specific for neurosyphilis. However, a single negative result should not be used to exclude the disease; repeat testing may be necessary.
Special Instructions
For assessment of intrathecally synthesized Treponema pallidum antibodies in spinal fluid, it is recommended to order Neurosyphilis IgG Antibody Index along with VDRL, Serum and Spinal Fluid. Submit specimen collected in vial 2, if possible, and note which vial the aliquot was obtained from if otherwise.
Limitations
The VDRL test on spinal fluid has a high percentage of false-negative results. A positive result indicates the presence of neurosyphilis, but negative results do not fully exclude the condition. It's crucial to consider clinical context and potentially perform additional testing.
FDA ApprovedNew York Approved
Methodology
Other (Flocculation/Agglutination)
Biomarkers
LOINC Codes
- 5290-2
- 5290-2
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
Sterile vial
Collection Instructions
Submit specimen in vial 2, note vial if different.
Causes for Rejection
Gross hemolysis, gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 14 days |